Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial.
Brief Summary: Borderline Personality Disorder (BDP) is a serious mental disorder that affects about 1-2% of the general population, and it is characterized by severe psychosocial impairment and a high mortality rate due to suicide. Currently, the most effective treatments for BPD are psychotherapy (cognitive behavior therapy - CBT -) and pharmacotherapy (often as an important adjunctive role, especially for diminution of symptoms such as affective instability, impulsivity, psychotic-like symptoms and self-destructive behavior). Nevertheless, although several drugs are used in these patients, these drugs induce an improvement of some symptoms but do not cause the remission of BPD. Thus, identification of novel treatments is needed.

The objective of this study is to examine the efficacy of Omacor® ( a mixture of omega-3-acid ethyl esters: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ) for BDP patients receiving CBT. Patients with BDP will be randomly allocated to the three arms of the study: 1- CBT+placebo, 2- CBT+Omacor 1680 mg/d, 3- CBT+Omacor 3360 mg/d. Follow up will last for 12 weeks. Assessment of affective symptoms, impulsivity and aggressivity will be carried out at baseline and at 2, 4, 6, 8, 10 and 12 weeks.


Options:
A: Arm Label: Intensive Group Analytic Psychotherapy; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group Analytic Psychotherapy | Arm Label: Intensive GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive transdiagnostic cognitive-behavioral group therapy | Arm Label: Wait-list control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive Group Analytic Psychotherapy; Assigned to Arm(s): Intensive Group Analytic Psychotherapy | Intervention Type: BEHAVIORAL; Name: Intensive transdiagnostic cognitive-behavioral group therapy; Assigned to Arm(s): Intensive GCBT
B: Arm Label: Psychosocial group intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 10 weekly group meetings, Behavioral: Outpatient counseling and support groups | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient counseling and support groups | Intervention Type: BEHAVIORAL; Name: 10 weekly group meetings; Assigned to Arm(s): Psychosocial group intervention | Intervention Type: BEHAVIORAL; Name: Outpatient counseling and support groups; Assigned to Arm(s): Control, Psychosocial group intervention
C: Arm Label: Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Escitalopram, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Omacor® | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omacor®; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: D